Identification | |||||
---|---|---|---|---|---|
Name | Alemtuzumab | ||||
Accession Number | DB00087 (BIOD00109, BTD00109) | ||||
Type | biotech | ||||
Description | Humanized monoclonal antibody specific to lymphocyte antigens. It is a recombinant DNA-derived humanized monoclonal antibody (Campath-1H) that is directed against the 21-28 kD cell surface glycoprotein,CD52. The Campath-1H antibody is an IgG1 kappa with human variable framework and constant regions, and complementarity-determining regions from a murine (rat) monoclonal antibody (Campath-1G). Campath is produced in mammalian cell (Chinese hamster ovary) suspension culture in a medium containing neomycin. | ||||
Structure |
|
||||
Categories (*) | |||||
Molecular Weight | 145453.8000 | ||||
Groups | approved | ||||
Monoisotopic Weight | Not Available | ||||
Pharmacology | |||||
Indication | Alemtuzumab (Campath) is a monoclonal antibody therapy used for treatment of B-cell chronic lymphocytic leukemia. | ||||
Mechanism of action | Campath binds to the CD52 antigen present on most B and T lymphocytes. This binding leads to antibody-dependent lysis of leukemic cells. | ||||
Absorption | Not Available | ||||
Protein binding | Not Available | ||||
Biotransformation | Most likely removed by opsonization via the reticuloendothelial system when bound to B or T lymphocytes | ||||
Route of elimination | Not Available | ||||
Toxicity | Not Available | ||||
Affected organisms | Not Available | ||||
Interactions | |||||
Drug Interactions |
|
||||
Food Interactions | Not Available |
CAMPATH-1 antigen | |
---|---|
Name | CAMPATH-1 antigen |
Gene Name | CD52 |
Pharmacological action | yes |
Actions | antibody |
References |
|
DTHybrid score | 0.3293 |
Low affinity immunoglobulin gamma Fc region receptor III-B | |
Name | Low affinity immunoglobulin gamma Fc region receptor III-B |
Gene Name | FCGR3B |
Pharmacological action | unknown |
Actions | Not Available |
References |
|
DTHybrid score | 1.5333 |
Complement C1r subcomponent | |
Name | Complement C1r subcomponent |
Gene Name | C1R |
Pharmacological action | unknown |
Actions | Not Available |
References | |
DTHybrid score | 1.4409 |
Complement C1q subcomponent subunit A | |
Name | Complement C1q subcomponent subunit A |
Gene Name | C1QA |
Pharmacological action | unknown |
Actions | Not Available |
References | |
DTHybrid score | 1.458 |
Complement C1q subcomponent subunit B | |
Name | Complement C1q subcomponent subunit B |
Gene Name | C1QB |
Pharmacological action | unknown |
Actions | Not Available |
References | |
DTHybrid score | 1.4589 |
Complement C1q subcomponent subunit C | |
Name | Complement C1q subcomponent subunit C |
Gene Name | C1QC |
Pharmacological action | unknown |
Actions | Not Available |
References | |
DTHybrid score | 1.4589 |
Low affinity immunoglobulin gamma Fc region receptor III-A | |
Name | Low affinity immunoglobulin gamma Fc region receptor III-A |
Gene Name | FCGR3A |
Pharmacological action | unknown |
Actions | Not Available |
References |
|
DTHybrid score | 1.5329 |
High affinity immunoglobulin gamma Fc receptor I | |
Name | High affinity immunoglobulin gamma Fc receptor I |
Gene Name | FCGR1A |
Pharmacological action | unknown |
Actions | Not Available |
References | |
DTHybrid score | 1.6208 |
Low affinity immunoglobulin gamma Fc region receptor II-a | |
Name | Low affinity immunoglobulin gamma Fc region receptor II-a |
Gene Name | FCGR2A |
Pharmacological action | unknown |
Actions | Not Available |
References |
|
DTHybrid score | 1.5414 |
Low affinity immunoglobulin gamma Fc region receptor II-b | |
Name | Low affinity immunoglobulin gamma Fc region receptor II-b |
Gene Name | FCGR2B |
Pharmacological action | unknown |
Actions | Not Available |
References | |
DTHybrid score | 1.5373 |
Low affinity immunoglobulin gamma Fc region receptor II-c | |
Name | Low affinity immunoglobulin gamma Fc region receptor II-c |
Gene Name | FCGR2C |
Pharmacological action | unknown |
Actions | Not Available |
References | |
DTHybrid score | 1.547 |